Protalix BioTherapeutics, Inc. (PLX) Gross margin 2016–2025
Protalix BioTherapeutics, Inc. (PLX) gross margin by fiscal year — reported gross profit divided by reported revenue.
48.8%FY2025 · since FY2016: 8.7% → 48.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 48.8% | -5.6 pp |
| FY2024 | 54.5% | -10.5 pp |
| FY2023 | 64.9% | +6.0 pp |
| FY2022 | 58.9% | +1.5 pp |
| FY2021 | 57.4% | -25.3 pp |
| FY2020 | 82.7% | +2.6 pp |
| FY2019 | 80.1% | +7.2 pp |
| FY2018 | 72.8% | +53.8 pp |
| FY2017 | 19.0% | +10.3 pp |
| FY2016 | 8.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice